Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

IntroductionThe vascular endothelial growth factor (VEGF) family of ligands and receptors (VEGFR) play an important role in tumor angiogenesis. Increased expression of angiogenic factors in tumors or in blood is associated with poor prognosis. The aim of this study was to investigate the role of VEGF-A and soluble VEGFR-2 (sVEGFR-2) as biomarkers in advanced non-small-cell lung cancer (NSCLC).MethodsWe studied 432 patients with advanced NSCLC (stages IIIB-IV) treated with cisplatin and docetaxel and 89 healthy age-matched controls. Blood samples were collected before chemotherapy, and VEGF-A and sVEGFR-2 levels were determined by ELISA.ResultsVEGF-A and sVEGFR-2 levels were higher in NSCLC patients than in the controls, but VEGF-A behaves as a better diagnostic biomarker. There were no significant associations between VEGF-A and sVEGFR-2 concentrations and clinical characteristics, such as ECOG-PS, gender, stage, histology, metastases, and treatment response. A patient subgroup characterized by a combination of high VEGF-A and low sVEGFR-2 levels exhibited the worst patient prognoses in terms of TTP and OS.ConclusionsVEGF-A and sVEGFR-2 levels were significantly higher in patients than in the controls. A combination of VEGF-A and sVEGFR-2 can be used as an independent prognostic biomarker in advanced NSCLC.

Original publication

DOI

10.1016/j.lungcan.2011.02.016

Type

Journal article

Journal

Lung cancer (Amsterdam, Netherlands)

Publication Date

11/2011

Volume

74

Pages

326 - 331

Addresses

Molecular Oncology Laboratory, Fundación para la Investigación del Hospital General Universitario, Valencia, Spain.

Keywords

Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression, Cisplatin, Taxoids, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Staging, Prognosis, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Biomarkers, Tumor, Docetaxel